Eflapegrastim clinical trials
Also written SPI-2012 and HM10460A.
How each study uses eflapegrastim is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the eflapegrastim studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 Sept 2022 · ROLVEDON · BLA 761148 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Spectrum Pharmaceuticals, Inc (6) · Hanmi Pharmaceutical Company Limited (1) · Eunseong Medical Foundation Good GANG-AN HOSPITAL (1)
Often tested with
Tested in the same studies.
Pegfilgrastim (3) · Docetaxel (1) · Cyclophosphamide (1) · Antineoplastic Agents (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test eflapegrastim.
- Oct 2027A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyPhase 2 · Spectrum Pharmaceuticals, Inc
Studies
Open first, then newest update. How each study uses eflapegrastim is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyRecruitingPhase 2Spectrum Pharmaceuticals, IncNCT04570423Written as Eflapegrastim
- Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After ChemotherapyRecruitingPhase 4Eunseong Medical Foundation Good GANG-AN HOSPITALNCT05949333Written as Eflapegrastim
- Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-CancerCompletedPhase 1Spectrum Pharmaceuticals, IncNCT04187898Written as Eflapegrastim
- Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast CancerCompletedPhase 2Spectrum Pharmaceuticals, IncNCT01724866Written as SPI-2012
- SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and CyclophosphamideCompletedPhase 3Spectrum Pharmaceuticals, IncNCT02953340Written as SPI-2012
- SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)CompletedPhase 3Spectrum Pharmaceuticals, IncNCT02643420Written as SPI-2012
- Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) ChemotherapyCompletedPhase 1Spectrum Pharmaceuticals, IncNCT03135951Written as SPI-2012
- Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean SubjectsCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT00998283Written as HM10460A 5μg/kg
Codes
What other systems call eflapegrastim · ClinicalTrials.gg INT006342
- MeSH (NLM) C583329eflapegrastimOne source NLM
- UNII (FDA) UT99UG9QJXEFLAPEGRASTIMConfirmed FDA, NLM, Wikidata
- RxNorm 2612526One source FDA
- Wikidata Q30314101eflapegrastimConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C103856EflapegrastimOne source FDA
- DrugBank DB15001One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583329 | eflapegrastim | One source NLM |
| UNII (FDA) | UT99UG9QJX | EFLAPEGRASTIM | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2612526 | — | One source FDA |
| Wikidata | Q30314101 | eflapegrastim | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C103856 | Eflapegrastim | One source FDA |
| DrugBank | DB15001 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.